James is joined by Dr. Paul-Peter Tak, Venture Partner at Flagship Pioneering and CEO of Kintai Therapeutics. Over a more than 25-year career in the life sciences, Paul-Peter has created and led multiple companies. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immuno-inflammation therapy area unit at GSK. Under Paul-Peter’s leadership, this unit brought more than 10 new mechanisms of action into the clinic. From 2016 until 2018, Paul-Peter was senior vice president of R&D pipeline, chief immunology officer, development leader, and co-chair of GSK’s scientific review board. He oversaw the creation of a new portfolio of medicines in oncology, with a focus on immuno-oncology, epigenetics, and cell and gene therapy.

Trained as a general internist, rheumatologist, and immunologist, Paul-Peter has held multiple professorships and has published extensively, with more than 550 papers in his name. He served as professor of medicine and chair of the department of clinical immunology and rheumatology at the Academic Medical Centre/University of Amsterdam for twelve years. He is a professor of medicine at the Amsterdam University Medical Center, honorary professor of rheumatology at Ghent University, and honorary senior visiting fellow at the University of Cambridge. He is a fellow of the Academy of Medical Sciences in the U.K.

Paul-Peter received his medical degree cum laude from the Free University in Amsterdam and his Ph.D. from Leiden University Medical Center.

For more information and content, check out our website www.hs.ventures. You can follow us on Twitter @HSVenture, on Instagram @hs.ventures, on Linkedin at HS. and you can email us at info@hs.live

You can get our host, Dr. James Somauroo, at www.jamessomauroo.com and you can follow him on Twitter @jamessomauroo, on Instagram @j_soms and on Linkedin at james-somauroo

Episode 35: The Story of Flagship Pioneering and The Future of Medicines 🧪